Modeling Cure Rate of Infectious Disease with or Without Co-Infection: An Application to Tuberculosis / Human Immuno Virus

Modeling Cure Rate of Infectious Disease with or Without Co-Infection: An Application to Tuberculosis / Human Immuno Virus

Olaosebikan, A.1; Aderoju, S.A.2* and Balogun, O.S.3

1, 2*Department of Statistics and Mathematical Sciences, Kwara State University, Malete, P.M.B. 1530, Ilorin, Kwara State, Nigeria. 3Department of Statistics and Operations Research, Modibbo Adamawa University of Technology, Yola, Adamawa State, Nigeria.

American Journal of Scientific Research and Essays

In this study, we examined the challenges of modeling infectious diseases using tuberculosis (TB) as a case study. The tuberculosis and tuberculosis co-infected with Human Immuno Virus (HIV) is one of the common health problems in the world. Time-to-event outcomes are common data type in medical research. The data examined time until a patient is cured of the disease having some patients right censored. With the nature of the data, the appropriate analysis is survival analysis method. The study aims at fitting appropriate models to the TB and TB/HIV co-infection data examining age and gender as factors influencing the cure rate of the disease. Hence, Kaplan-Meier estimation, Cox PH and some parametric models were adopted in the study. The result shows that among the parametric models, generalized gamma fit TB data best and there is no significant difference in the survival rate of male and female while gamma fit TB co-infected with HIV best and there is a significant difference in the male and female patient. However, Cox PH model (having smaller AIC) performs better than all the parametric models considered (for both data) in this study though with the same conclusion.

Keywords: Survival analysis, TB, HIV co-infection, parametric, Kaplan_Meier, Cox PH

Free Full-text PDF

How to cite this article:
Olaosebikan, A.; Aderoju, S.A. and Balogun, O.S.. Modeling Cure Rate of Infectious Disease with or Without Co-Infection: An Application to Tuberculosis / Human Immuno Virus. American Journal of Scientific Research and Essays, 2019 4:26. DOI:10.28933/ajsre-2019-06-1406


1 Anderson R.M and May R.M, (1992) Infectious Disease of Humans: Dynamics and control, New York: Oxford University press.
2 Mayo clinic (2019), “Tuberculosis – Symptoms and causes” Mayo Foundation for Medical Education and Research (MFMER);
3 Corbett E.L, Watt C.J, Walker N., Maher D., Williams B.G., Raviglione M.C.and Dye C., (2003). The Growing Burden Of Tuberculosis: Global Trend and Interactions with the HIV epidemic. Arch Intern Med.; 163(9):1009-21.
4 Peterson E. et al., (2019). “It’s TIME” — International Journal of Infectious Diseases Tuberculosis Theme Series; International Journal Of Infectious Diseases, 80:S1-S5.
5 Abera, B., Kate, F., Zelalam, H. and Andrew, F. (2009). The association of TB with HIV infection in Oromia Regional National State, Ethiopia in 2006/7. Journal of Ethiopia Health Dev., 23(1): 63-67.
6 Kapata, N., Chanda-Kapata, P. & Michelo, C. (2013). The social determinants of Tuberculosis and their association with TB/HIV co-infection in Lusaka, Zambia. Medical Journal of Zambia, 40(2): 48-54.
7 Straetemans, M., Bierranbach, A. L., Nagelkerke, N., Glaziou, P. & van der Weff M. J. (2010). The effect of Tuberculosis on Mortality in HIV positive people: A meta-analysis. PLoS ONE, 5(12): 1-10.
8 Zubairu, L. & Musa, B. (2009). Prevalence and Predictors of Tuberculosis co-infection among HIV-seropositive patients attending the Aminu Kano Teaching Hospital, Northern Nigeria. J. Epidemiol.,19(2): 81-87.
9 Mashimbye Lawrence (2010). Tuberculosis (TB) treatment outcomes in adult TB patients attending a rural HIV clinic in South Africa (Bushbuckridge). Available at website:
10 Refera Hailu (2012). Survival and risk factors of HIV/TB co-infected patients under antiretroviral therapy in Ambo Hospital, Ethiopia. Master’s thesis (unpublished), Department of Statistics, Addis Ababa University.
11 Fatmawati & Hengki, T. (2016). An optimal treatment control of TB-HIV co-infection. International Journal of Mathematics and Mathematical Sciences, 2016: ID8261208.
12 Gesesew, H., Tsehaineh, B., Massa, D., Tesfay, A., Kahsay, H. & Mwanri, L. (2016). The role of social determinants on Tuberculosis/HIV co-infection mortality in Southwest Ethopia: a retrospective Cohort study. BMC Research Notes, 9(1):89
13 Fatmawati & Hengki, T. (2017). Optimal control of HIV resistance and tuberculosis co-infection using treatment intervention, Asian Pacific Journal of Tropical Disease, 7(6): 366-373.
14 Janida, M.A., Lawson, L., Nnodu, O.O., Ajani, M.N., Umobong, E. O., Fredrick, C.C., Adelaiye, R., Nafarda, W.D., Abdulraham, S. T., Okechukwu, J. N., Tafida, I. T., Bashir, I., Baamlong, N. D., Gurgel, R.Q., Yassin, M.A., Oladimeji, O. & Cuevas, L. E. (2015): Treatment outcome of patients co-infected with Tuberculosis and HIV in Abuja, Nigeria. Nigerian Journal of Basic and Clinical Sciences, 11(2): 72-75.
15 Shobowale, O., Elikwu, C.J. & Adegunle, B. (2015). Tuberculosis and HIV co-infection in a Tertiary Hospital in South Western Nigeria. International Journal of Medical and Biomedical Science, 3(1): 1-4
16 Yu, B., Tiwari, R. C., Cronin, K. Z. & Feuer, E. J. (2004). Cure fraction estimation from the mixture cure rate models for grouped survival data. Statistics in Medicine, 23:1733-1747.
17 Chen, Tai-Tsang (2016). Predicting analysis times in randomized clinical trials with cancer immunotherapy. BMC Medical Research Methodology, 16(12): 1-10.
18 Elfaki, F. A. M., Abobakar Amar, Azram, M. & Usman, M. (2013). Survival model for partly interval-censored data with application to Anti D in Rhesus D Negative studies. International Scholarly and Scientific Research and Innovation, 7(5): 895-898.
19 Rodrigues, J., Balakrishnan, N., Cordeiro, G. M., de Castro, M. & Cancho, V. G. (2015). Latent cure rate model under repair system and threshold effect. Journal of Statistical Computation and Simulation, 85(14): 2860-2873.
20 Klebanov, L. B., Rachev, S. T. & Yakovlev, A. (1993). A Stochastic model of radiation Carcinogenesis: Latent time distributions and their properties. Math. Biosci., 18: 51-75.
21 Kim, S., Chen, M-H. & Dey, D. K. (2011). A new threshold regression model for survival data with a cure fraction. Lifetime Data Analysis, 17: 101-122.
22 Rodrigues, J., de Castro, M., Balakrishnan, M. & Cancho, V. G. (2011). Destructive weighted Poisson cure rate model. Lifetime Data Anal, 17(3): 333-346.
23 Li, D., Wang, X. and Dey, D. K. (2016). A flexible cure rate model for spatially correlated survival data based on generalized extreme value distribution and Gaussian process priors. Biometrical Journal; 58 (5), 1-20.
24 Kleinbaum, D.G. and Klein M. (2012): Survival Analysis; A self-learning Text, Third Edition, Statistics for Biology and Health, Springer Science + Business Media; ISBN 9781441966452 .
25 Cox D.R.,(1972). Regression Models and Lifetables. J Royal Stati Society 34: 187-220.
26 Weibull W., (1951). “A Statistical Distribution Function of Wide Applicability”. Journal of Applied Mechanics, 18:293-297.
27 Galton, F. (1879). The geometric mean in vital and social statistics. Proceedings of the Royal Society of London 29, 365–7.
28 Aitchison J. and Brown J.A.C., (1957). “The Log-normal Distribution”, Cambridge University Press.
29 Lienhard J.H and Meyer P.L., (1967). A Physical Basis For The Generalized gamma, Quarterly Of Applied Mathematics; Vol. XXV:3.
30 Balogun O.S. and Jolayemi, E. T. (2017), Modelling Cure Rate Model for TB with HIV co-infection. The Pacific Journal of Science and Technology, 18(1):288-299.
31 Terry M. Therneau, Patricia M. Grambsch (2000). Modeling Survival Data: Extending the Cox Model. Springer, New York. ISBN 0-387-98784-3.
32 Christopher Jackson (2016). flexsurv: A Platform for Parametric Survival Modeling in R. Journal of Statistical Software, 70(8), 1-33. doi:10.18637/jss.v070.i08
33 R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL

Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details).

This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.